信立泰：SAL0139片临床试验获批

Core Viewpoint - The company, Xinlitai, has received approval from the National Medical Products Administration for its innovative small molecule drug SAL0139 tablets to conduct clinical trials for the treatment of hyperlipidemia [1] Group 1 - The drug SAL0139 is developed independently by the company [1] - The clinical trial approval is a significant step towards the drug's potential market entry [1] - The company will conduct the clinical trials in accordance with national drug registration regulations and requirements [1]